NICE rejects Boehringer's new lung cancer drug in draft guidance
This article was originally published in Scrip
Executive Summary
NICE has turned down Boehringer Ingelheim's recently approved lung cancer drug Vargetef (nintedanib) in draft guidance because it believes the price is too high for the benefit the product offers.